The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preclinical activity of new investigational drug ONC201 in triple-negative and non-triple negative and BRCA1-deficient breast cancer cells.
 
Marie D Baumeister
No Relationships to Disclose
 
Jessica Wagner
No Relationships to Disclose
 
Varun V. Prabhu
No Relationships to Disclose
 
Christina Leah B. Kline
No Relationships to Disclose
 
Joshua E. Allen
Employment - Oncoceutics
Leadership - Oncoceutics
Stock and Other Ownership Interests - Oncoceutics
 
David T. Dicker
No Relationships to Disclose
 
Wafik S. El-Deiry
Stock and Other Ownership Interests - Oncoceutics; p53-Therapeutics
Consulting or Advisory Role - Morphotek
Patents, Royalties, Other Intellectual Property - I hold patents and have submitted patents relevant to my academic laboratory research. However, these patent have no relationship with my GI ASCO presentation.